Drug Profile
Ezabenlimab - Boehringer Ingelheim
Alternative Names: BI-754091Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Amal Therapeutics; Boehringer Ingelheim; National Health Research Institutes
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anal cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Phase I/II Colorectal cancer
- Phase I Adenocarcinoma; Liver cancer; Neuroendocrine tumours; Small cell lung cancer
- No development reported Head and neck cancer; Non-small cell lung cancer
Most Recent Events
- 22 Apr 2024 Boehringer Ingelheim plans a phase III Brightline-3 trial for Soft tissue sarcoma (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) (PO), in June 2024 (NCT06370871)
- 31 Jan 2024 Boehringer Ingelheim initiates enrolment in a phase I trial for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (NCT06091930) (IV)
- 18 Jan 2024 Efficacy and adverse events data from the phase II INTERACT-ION trial in Anal cancer presented at the Gastrointestinal Cancers Symposium ASCO-GCS-2024)